Clinical Trial Market Research Reports & Industry Analysis
Clinical Trial Industry Research & Market Reports
-
Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
... 'Collagenase 3 - Drugs In Development, 2022'; Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) pipeline Target constitutes close to 7 molecules. Out of which approximately 5 molecules are developed by companies and ... Read More
-
Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
... the recently published report 'Histone Deacetylase 6 - Drugs In Development, 2022'; Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) pipeline Target constitutes close to 53 molecules. Out of ... Read More
-
Idiopathic Pulmonary Fibrosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... Development, 2022, provides an overview of the Idiopathic Pulmonary Fibrosis (Respiratory) pipeline landscape. Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal disease characterized by inflammation and scarring of lung tissue and loss of lung ... Read More
-
Bronchiectasis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... overview of the Bronchiectasis (Respiratory) pipeline landscape. Bronchiectasis is a chronic condition where the walls of the bronchial tubes are permanently damaged. These damage allow bacteria and mucus to build up in lungs. Bronchiectasis is ... Read More
-
Hypertrophic Cardiomyopathy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... provides an overview of the Hypertrophic Cardiomyopathy (Cardiovascular) pipeline landscape. Hypertrophic cardiomyopathy (HCM) is a disease in which the heart muscle (myocardium) becomes abnormally thick (hypertrophied). The thickened heart muscles make it harder for the ... Read More
-
Atherosclerosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... overview of the Atherosclerosis (Cardiovascular) pipeline landscape. Atherosclerosis (or arteriosclerotic vascular disease) is a condition where the arteries become narrowed and hardened due to an excessive build up of plaque around the artery wall. The ... Read More
-
Head and Neck Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... Drugs In Development, 2022, provides an overview of the Head And Neck Cancer (Oncology) pipeline landscape. Head and Neck Cancer is a cancer that arises in the head or neck region (in the nasal cavity, ... Read More
-
Oropharyngeal Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... provides an overview of the Oropharyngeal Cancer (Oncology) pipeline landscape. Oropharyngeal cancer is a disease which malignant cells form in the tissue of oropharynx. Oropharynx is a middle part of the throat which includes the ... Read More
-
Fallopian Tube Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... Development, 2022, provides an overview of the Fallopian Tube Cancer (Oncology) pipeline landscape. Fallopian tube cancer is also called tubal cancer. It develops in the fallopian tubes, which serve as a connection between the ovaries ... Read More
-
Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
... 2022 Update Summary Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) - Retinoic acid receptor alpha (RARA) is a nuclear receptor that is encoded ... Read More
-
Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
... or Cathepsin B1 or CTSB or EC 3.4.22.1) pipeline Target constitutes close to 5 molecules. Out of which approximately 4 molecules are developed by companies and remaining by the universities/institutes. The latest report Cathepsin B ... Read More
-
Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
... Antecedent or F11 or EC 3.4.21.27) - Factor XI or plasma thromboplastin antecedent is the zymogen form of factor Xia. Factor XI triggers the middle phase of the intrinsic pathway of blood coagulation by activating ... Read More
-
Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
... or RPD3 2 or HDAC3 or EC 3.5.1.98) - Histone deacetylase 3 is an enzyme encoded by the HDAC3 gene. Histone deacetylation gives a tag for epigenetic repression and plays an important role in transcriptional ... Read More
-
India AI-based Clinical Trials Solution Provider Market: Prospects, Trends Analysis, Market Size and Forecasts up to 2028
... study of the India market. Moreover, the report provides deep insights into demand forecasts, market trends, and, micro and macro indicators in the India market. Also, factors that are driving and restraining the AI-based clinical ... Read More
-
Ireland AI-based Clinical Trials Solution Provider Market: Prospects, Trends Analysis, Market Size and Forecasts up to 2028
... study of the Ireland market. Moreover, the report provides deep insights into demand forecasts, market trends, and, micro and macro indicators in the Ireland market. Also, factors that are driving and restraining the AI-based clinical ... Read More
-
South Korea AI-based Clinical Trials Solution Provider Market: Prospects, Trends Analysis, Market Size and Forecasts up to 2028
... and competitive study of the South Korea market. Moreover, the report provides deep insights into demand forecasts, market trends, and, micro and macro indicators in the South Korea market. Also, factors that are driving and ... Read More
-
Psoriatic Arthritis Clinical Trial Analysis by Trial Phase, Trial Status, Trial Counts, End Points, Status, Sponsor Type, and Top Countries, 2022 Update
... Trial Status, Trial Counts, End Points, Status, Sponsor Type, and Top Countries, 2022 Update provides an overview of Psoriatic Arthritis Clinical trials scenario. This report provides top line data relating to the clinical trials on ... Read More
-
Rotavirus Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... provides an overview of the Rotavirus Infections (Infectious Disease) pipeline landscape. Rotavirus is a virus that infects the bowels. Rotavirus is the most common cause of severe diarrhea among infants and children. Transmission of rotavirus ... Read More
-
Chikungunya Fever Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... provides an overview of the Chikungunya Fever (Infectious Disease) pipeline landscape. Chikungunya is a viral disease transmitted to humans by the bite of infected Aedes aegypti mosquitoes. Chikungunya virus (CHIKV) is a member of the ... Read More
-
Inclusion Body Myositis (IBM) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... Drugs In Development, 2022, provides an overview of the Inclusion Body Myositis (IBM) (Musculoskeletal Disorders) pipeline landscape. Inclusion Body Myositis (IBM) is one of the inflammatory myopathies that involve inflammation of the muscles or associated ... Read More
-
Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... Drugs In Development, 2022, provides an overview of the Thrombotic Thrombocytopenic Purpura (Musculoskeletal Disorders) pipeline landscape. Thrombotic Thrombocytopenic Purpura (TTP) is a rare blood disorder characterized by clotting in small blood vessels of the body ... Read More
-
Pheochromocytoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... overview of the Pheochromocytoma (Oncology) pipeline landscape. Pheochromocytoma is a rare, usually non-cancerous (benign) tumor that develops in cells in the center of an adrenal gland. Symptoms include high blood pressure, severe headache, tremors, shortness ... Read More
-
Basal Cell Carcinoma (Basal Cell Epithelioma) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... (Basal Cell Epithelioma) - Drugs In Development, 2022, provides an overview of the Basal Cell Carcinoma (Basal Cell Epithelioma) (Oncology) pipeline landscape. Basal cell carcinoma is a type of skin cancer which begins in the ... Read More
-
Stroke Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... overview of the Stroke (Cardiovascular) pipeline landscape. Stroke is a condition in which the brain cells suddenly die because of a lack of oxygen. Symptoms occur rapidly and usually last a short time, from a ... Read More
-
Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
... 2022 Update Summary According to the recently published report 'Retinoic Acid Receptor Gamma - Drugs In Development, 2022'; Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 ... Read More
Research Assistance
